UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended August 31, 1997.
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______________ to _______________.
Commission file Number 0-12515.
BIOMET, INC.
(Exact name of registrant as specified in its charter)
Indiana 35-1418342
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
Airport Industrial Park, P.O. Box 587, Warsaw, Indiana 46581-0587
(Address of principal executive offices)
(219) 267-6639
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
The number of shares outstanding of each of the issuer's classes of common
stock, as of August 31, 1997:
Common Shares - No Par Value 111,516,359 Shares
(Class) (Number of Shares)
Rights to Purchase Common Shares 111,516,359 Rights
(Class) (Number of Shares)
BIOMET, INC.
CONTENTS
Pages
Part I. Financial Information
Item 1. Financial Statements:
Consolidated Balance Sheets 1-2
Consolidated Statements of Income 3
Consolidated Statements of Cash Flows 4
Notes to Consolidated Financial Statements 5-7
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations 8-9
Part II. Other Information 10-11
Signatures 12
Index to Exhibits 13
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
BIOMET, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
as of August 31, 1997 and May 31, 1997
(in thousands)
ASSETS
August 31, May 31,
1997 1997
---------- -------
Current assets:
Cash and cash equivalents $ 86,631 $ 82,034
Investments 51,348 41,237
Accounts and notes receivable, net 161,881 162,135
Inventories 153,243 151,523
Prepaid expenses and other 27,770 27,311
------- -------
Total current assets 480,873 464,240
------- -------
Property, plant and equipment, at cost 159,860 152,839
Less, Accumulated depreciation 65,955 61,927
------- -------
Property, plant and equipment, net 93,905 90,912
------- -------
Investments 40,955 44,527
Intangible assets, net 5,366 5,787
Excess acquisition cost over fair value
of acquired net assets, net 27,348 20,306
Other assets 3,040 2,584
------- -------
Total assets $ 651,487 $ 628,356
======= =======
The accompanying notes are a part of the consolidated financial statements.
BIOMET, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
as of August 31, 1997 and May 31, 1997
(in thousands)
LIABILITIES AND SHAREHOLDERS' EQUITY
August 31, May 31,
1997 1997
---------- -------
Current liabilities:
Short-term borrowings $ 5,881 $ 5,568
Accounts payable 14,216 17,140
Accrued income taxes 25,828 12,181
Accrued wages and commissions 10,472 12,232
Other accrued expenses 26,834 25,793
------- -------
Total current liabilities 83,231 72,914
Long-term liabilities:
Deferred federal income taxes 2,346 2,229
Other liabilities 332 385
------- -------
Total liabilities 85,909 75,528
------- -------
Contingencies (Note 6)
Shareholders' equity:
Common shares 74,132 73,587
Additional paid-in capital 16,001 16,001
Retained earnings 489,442 472,450
Net unrealized appreciation of
available-for-sale securities 1,215 1,040
Cumulative translation adjustment (15,212) (10,250)
------- -------
Total shareholders' equity 565,578 552,828
------- -------
Total liabilities and shareholders' equity $ 651,487 $ 628,356
======= =======
The accompanying notes are a part of the consolidated financial statements.
BIOMET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
for the three months ended August 31, 1997 and 1996
(in thousands, except per share amounts)
1997 1996
---- ----
Net sales $149,529 $137,178
Cost of sales 46,622 44,428
------- -------
Gross profit 102,907 92,750
Selling, general and administrative expenses 52,870 49,889
Research and development expense 5,886 6,518
------- -------
Operating income 44,151 36,343
Other income, net 2,326 2,351
------- -------
Income before income taxes 46,477 38,694
Provision for income taxes 17,216 14,607
------- -------
Net income $ 29,261 $ 24,087
======= =======
Earnings per share, based on
the weighted average number
of shares outstanding during
the periods presented $ .26 $ .21
==== ====
Weighted average number of shares 111,405 115,739
======= =======
Cash dividend per common share $ .11 $ --
==== ====
The accompanying notes are a part of the consolidated financial statements.
BIOMET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
for the three months ended August 31, 1997 and 1996
(in thousands)
1997 1996
---- ----
Cash flows from (used in) operating activities:
Net income $ 29,261 $ 24,087
Adjustments to reconcile net income to
net cash from operating activities:
Depreciation 3,395 3,415
Amortization 1,340 1,813
Gain on sale of investments, net (258) (62)
Changes in current assets and current liabilities,
excluding effects of acquisitions:
Accounts and notes receivable, net (1,059) 1,420
Inventories (1,224) 1,411
Prepaid expenses and other (428) (2,858)
Accounts payable (2,504) (2,394)
Accrued income taxes 14,163 13,436
Accrued wages and commissions (1,592) (21)
Other accrued expenses 767 (3,159)
------- ------
Net cash from operating activities 41,861 37,088
------- ------
Cash flows from (used in) investing activities:
Cash proceeds from sales and maturities of
investments 4,911 11,622
Purchases of investments (10,880) (9,004)
Capital expenditures (4,997) (3,458)
Business acquisitions, net of cash acquired (13,133) (4,667)
Increase in other assets (635) (568)
Other (51) (227)
------- ------
Net cash used in investing activities (24,785) (6,302)
------- ------
Cash flows from (used in) financing activities:
Increase (decrease) in short-term borrowings, net 866 (69)
Issuance of common shares 523 2,870
Cash dividend (12,256) --
Purchase of common shares -- (11,375)
------- ------
Net cash used in financing activities (10,867) (8,574)
------- ------
Effect of exchange rate changes on cash (1,612) 493
------- ------
Increase in cash and cash equivalents 4,597 22,705
Cash and cash equivalents, beginning of year 82,034 106,068
------- -------
Cash and cash equivalents, end of period $ 86,631 $128,773
======= =======
The accompanying notes are a part of the consolidated financial statements.
BIOMET, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1: OPINION OF MANAGEMENT.
The accompanying consolidated financial statements include the
accounts of Biomet, Inc. and its wholly owned subsidiaries
(individual and collectively referred to as the "Company"). The
unaudited consolidated financial statements have been prepared
in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form
10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not
include all of the information and notes required by generally
accepted accounting principles for complete financial
statements. In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary
for a fair presentation have been included. Operating results
for the three month period ended August 31, 1997 are not
necessarily indicative of the results that may be expected for
the fiscal year ending May 31, 1998. For further information,
refer to the consolidated financial statements and notes thereto
included in the Company's Annual Report on From 10-K for the
fiscal year ended May 31. 1997.
The accompanying consolidated balance sheet at May 31, 1997, has
been derived from the audited Consolidated Financial Statements
at that date, but does not include all disclosures required by
generally accepted accounting principles.
NOTE 2: INVENTORIES.
Inventories at August 31, 1997 and May 31, 1997 are as follows:
August 31, May 31,
1997 1997
---------- -------
(in thousands)
Raw materials $ 21,176 $ 20,958
Work in process 18,038 16,546
Finished goods 66,824 64,992
Consigned inventory 47,205 49,027
------- -------
$153,243 $151,523
======= =======
NOTE 3: INCOME TAXES.
The difference between the reported provision for income taxes
and a provision computed by applying the federal statutory rate
to pre-tax accounting income is primarily attributable to state
income taxes, tax benefits relating to operations in Puerto
Rico, tax-exempt income and tax credits.
NOTE 4: COMMON SHARES.
During the three months ended August 31, 1997, the Company
issued 191,774 Common Shares upon the exercise of outstanding
stock options for proceeds aggregating $523,474.
BIOMET, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, continued
NOTE 5: ACQUISITIONS.
On June 1, 1997, the Company completed the acquisition of one of
its foreign distributors. The purchase price consisted of $13.1
million cash. The excess acquisition cost over fair value of
acquired net assets at the acquisition date approximated $8.5
million. The acquisition has been accounted for using the
purchase method of accounting with the operating results
included in the Company's consolidated financial statements from
the date of acquisition. Pro forma consolidated results of
operations are not presented as the amounts are not materially
different from the Company's historical results.
NOTE 6: CONTINGENCIES.
In January 1996, a jury returned a verdict in favor of Raymond
G. Tronzo ("Tronzo") awarding him approximately $55 million on
his patent and state law claims. On October 29,1996, the United
States District Court for the Southern District of Florida
entered a judgment, which implemented and reduced the jury
verdict, awarding $30.2 million to Tronzo on his state law
claims, including compensatory damages of approximately $7.1
million, punitive damages of $20 million, and prejudgment
interest. The trial court dismissed, with prejudice, Tronzo's
claim based upon unjust enrichment. The trial court denied the
Company's motion challenging the validity of Tronzo's patent.
Tronzo was awarded an additional $6.3 million judgment for
patent infringement, including a fifty percent enhancement based
upon willfulness. The trial court also granted an injunction
prohibiting future manufacture, use, promotion or sale, in the
United States, of the finned version of the Mallory-Head
acetabular cup, the device found to have infringed the Tronzo
patent. The U.S. Court of Appeals for the Federal Circuit (the
"Federal Circuit") denied the Company's motion to stay the
injunction pending the conclusion of the appeal. The
Mallory-Head finned acetabular cup accounted for a relatively
small portion of the Company's annual sales. The Company is
vigorously pursuing its appeal before the Federal Circuit on
both the patent and state law claims. The briefing by both
parties in the appeal was completed in the Federal Circuit in
June 1997 and oral arguments were held in September 1997. It is
anticipated that the Federal Circuit will issue its final
decision on the appeal sometime in early to mid calendar 1998.
In connection with the District Court's final judgment and its
order granting a stay of enforcement and execution of the
judgment, the Company was required to deliver to an escrow agent
investments with a value no less than $36.6 million to be held
in escrow, invested and disbursed for the benefit of the
plaintiff pending the outcomes of all appeals. The $36.6 million
of investments, which are restricted under the terms of the
escrow agreement, are included in investments on the Company's
consolidated balance sheet as of August 31 and May 31, 1997.
BIOMET, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, concluded
NOTE 6: CONTINGENCIES, concluded.
On June 2, 1997, the Company announced the entry of a jury
verdict against it in the United States District Court of New
Jersey in an action brought by Orthofix SRL ("Orthofix") against
the Company and its wholly-owned subsidiaries, Electro-Biology,
Inc. ("EBI") and EBI Medical Systems, Inc. ("EBIMS"), (the
"Biomet Group") related to the events surrounding the expiration
of a distribution agreement under which EBIMS distributed
Orthofix's external fixation devices in the United States. The
jury found that, notwithstanding Orthofix's refusal to renew the
distribution agreement, EBIMS's commencement of development
activities of a new external fixation system prior to the
expiration of the contract, constituted a breach of the
distribution agreement. The jury awarded compensatory damages
against the Biomet Group for breach of contract and related
claims of approximately $49 million and punitive damages of $100
million. The jury also concluded that Orthofix breached the
distribution agreement and tortiously interfered with EBIMS's
economic relations, but awarded only nominal damages to the
Biomet Group. With respect to certain non-jury issues, the trial
court entered an order denying Orthofix's motions for enhanced
and/or treble damages and attorneys' fees. The trial court also
granted Orthofix's motion for prejudgment interest, but only on
the compensatory portion of the damages commencing from November
29, 1995. On September 2, 1997, the trial court entered an
amended judgment reducing to $50 million, the $100 million in
punitive damages awarded to Orthofix by the jury. The Company
is appealing the final amended judgment entered against the
Biomet Group to the Federal Circuit.
Based on the information currently available and advice from
legal counsel, management believes that the trial court's
judgments in the Tronzo and Orthofix cases will not be upheld
upon appeal. Therefore, no amounts related to these two cases
have been recorded in the Company's financial statements, except
for estimated legal costs associated with the appeal process. If
the Company is unsuccessful in its appeal of either, or both, of
these cases, the ultimate liabilities could be material to the
operating results in the period such losses are recognized. The
Company's cash, cash equivalents and investments are adequate to
address the payment of any losses that could ultimately be
determined with respect to these two cases.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
FINANCIAL CONDITION AS OF AUGUST 31, 1997
The Company's cash and investments increased $11,136,000 to
$178,934,000 at August 31, 1997, despite the $12,256,000 cash
dividend paid during the first quarter.
Cash flows provided by operating activities were $41,861,000 for
the first three months of fiscal 1998 compared to $37,088,000 in
1997. The primary sources of 1998 cash flows from operating
activities were net income and an increase in accrued income
taxes. Accrued income taxes increase in the first quarter
because there is no federal tax estimate due in the first
quarter.
Cash flows used in investing activities were $24,785,000 for the
first three months of fiscal 1998 compared to $6,302,000 in
1997. The primary source of cash flows from investing
activities were sales and maturities of investments offset by
purchases of investments, purchases of capital equipment and a
business acquisition (See Note 5 of the Notes to Consolidated
Financial Statements).
Cash flows used in financing activities were $10,867,000 for the
first three months of fiscal 1998 compared to $8,574,000 in
1997. The primary use of cash flows from financing activities
was the cash dividend paid in the first quarter. In June 1997,
the Company's Board of Directors declared a cash dividend of
eleven cents ($.11) per share payable to shareholders of record
at the close of business on July 11, 1997. In January 1997, the
Company's Board of Directors authorized the purchase of up to an
additional $60,000,000 of the outstanding Common Shares of the
Company in open market or privately negotiated transactions
through the close of business on January 28, 1998. During this
quarter, the Company did not purchase any additional Common
Shares, and has approximately $38,000,000 under the
authorization for future purchases. Future purchases, if any,
will be dependent on market conditions.
Currently available funds, together with anticipated cash flows
generated from future operations, are believed to be adequate to
cover the Company's anticipated cash requirements, including
capital expenditures, research and development costs, purchases
of Common Shares under the repurchase program and litigation
settlements, if any.
RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED AUGUST 31, 1997
AS COMPARED TO THE THREE MONTHS ENDED AUGUST 31, 1996
Net sales increased 9% to $149,529,000 for the three-month
period ended August 31, 1997, from $137,178,000 for the same
period last year. Elective surgery-related products appear to be
influenced to some degree by seasonal factors, as the number of
elective orthopedic procedures decline during the summer months
and the holiday season. The Company's U.S.-based revenue
increased 10% to $111,196,000 during the first three months,
while foreign sales increased 6% to $38,333,000, net of a
negative foreign exchange adjustment of $1,400,000. Biomet's
worldwide sales of reconstructive products during the first
three months of fiscal 1998 were $87,292,000, representing a 7%
increase compared to the first three months of last year. This
increase was primarily a result of Biomet's continued
penetration of the reconstructive device market led by the Maxim
Total Knee System and the Alliance Hip System. Sales of
fixation products were $35,278,000 for the first three months of
fiscal 1998, representing a 7% increase as compared to the same
period in 1997. Sales of spinal products were $7,652,000 for
the first three months of fiscal 1998, representing an 11%
increase as compared to the same period in 1997. The Company's
sales of other products totaled $19,307,000, representing a 25%
increase over the first three months of fiscal year 1997,
primarily as a result of increased sales of arthroscopic and
soft goods products and the Indiana Tome Carpal Tunnel Release
System.
Cost of sales decreased as a percentage of net sales to 31.2%
for the first three months of fiscal 1998 from 32.4% last year
primarily as result of increased sales of higher margin
products, increased in-house manufacturing efficiencies and
improved margins realized through acquisitions of international
distributors. Selling, general and administrative expenses
decreased as a percentage of net sales to 35.4%, compared to
36.4% for the first three months of last year. This reduction
is principally the result of the consolidation of the operations
of Kirschner into various other subsidiaries and reduced legal
costs. Research and development expenditures decreased during
the first three months to $5,886,000 reflecting the completion
or termination of several research and development projects.
Operating income rose 21% from $36,343,000 for the first three
months of fiscal 1997, to $44,151,000 for the first three months
of fiscal 1998, corresponding to the increase in net sales.
Other income decreased $25,000 for the first three months of
fiscal year 1998 compared to the prior year's first three
months. The effective income tax rate decreased to 37.0% for
the current period compared to 37.8% for the same period in
fiscal 1997.
These factors resulted in a 21% increase in net income to
$29,261,000 from $24,087,000 for the first three months of
fiscal 1998 as compared to the same period in fiscal 1997 .
Earnings per share increased 24%, from $.21 to $.26 for the
periods presented.
OTHER SIGNIFICANT EVENTS.
On May 19, 1997, Biomet and Merck KGaA, Darmstadt, Germany,
announced their intention to enter into a joint venture to which
Biomet and Merck KGaA each would contribute its existing
European orthopedic operations. The joint venture with Merck
KGaA, which is subject to the negotiation of a definitive
agreement, certain regulatory approvals and approval by the
Boards of Directors of both companies, would operate as
"Biomet-Merck" and ownership would be shared 50/50. Merck KGaA
would bring to this venture an extensive array of chemical,
biological, pharmaceutical and orthopedic technologies and
products. Pro forma sales of the joint venture are estimated to
approach $200 million. At this point in our discussions, the
joint venture appears to provide an excellent strategic fit
between Biomet's European operations and Merck KGaA's
biomaterials division in terms of product lines, geographic
distribution and core competencies. The closing of this
transaction is currently anticipated to occur in December 1997.
PART II. OTHER INFORMATION
Item 1: Legal Proceedings.
In January 1996, a jury returned a verdict in favor of Raymond
G. Tronzo ("Tronzo") awarding him approximately $55 million on
his patent and state law claims. On October 29,1996, the United
States District Court for the Southern District of Florida
entered a judgment, which implemented and reduced the jury
verdict, awarding $30.2 million to Tronzo on his state law
claims, including compensatory damages of approximately $7.1
million, punitive damages of $20 million, and prejudgment
interest. The trial court dismissed, with prejudice, Tronzo's
claim based upon unjust enrichment. The trial court denied the
Company's motion challenging the validity of Tronzo's patent.
Tronzo was awarded an additional $6.3 million judgment for
patent infringement, including a fifty percent enhancement based
upon willfulness. The trial court also granted an injunction
prohibiting future manufacture, use, promotion or sale, in the
United States, of the finned version of the Mallory-Head
acetabular cup, the device found to have infringed the Tronzo
patent. The U.S. Court of Appeals for the Federal Circuit (the
"Federal Circuit") denied the Company's motion to stay the
injunction pending the conclusion of the appeal. The
Mallory-Head finned acetabular cup accounted for a relatively
small portion of the Company's annual sales. The Company is
vigorously pursuing its appeal before the Federal Circuit on
both the patent and state law claims. The briefing by both
parties in the appeal was completed in the Federal Circuit in
June 1997 and oral arguments were held in September 1997. It is
anticipated that the Federal Circuit will issue its final
decision on the appeal sometime in early to mid calendar 1998.
In connection with the District Court's final judgment and its
order granting a stay of enforcement and execution of the
judgment, the Company was required to deliver to an escrow agent
investments with a value no less than $36.6 million to be held
in escrow, invested and disbursed for the benefit of the
plaintiff pending the outcomes of all appeals. The $36.6 million
of investments, which are restricted under the terms of the
escrow agreement, are included in investments on the Company's
consolidated balance sheet as of August 31 and May 31, 1997.
On June 2, 1997, the Company announced the entry of a jury
verdict against it in the United States District Court of New
Jersey in an action brought by Orthofix SRL ("Orthofix") against
the Company and its wholly-owned subsidiaries, Electro-Biology,
Inc. ("EBI") and EBI Medical Systems, Inc. ("EBIMS"), (the
"Biomet Group") related to the events surrounding the expiration
of a distribution agreement under which EBIMS distributed
Orthofix's external fixation devices in the United States. The
jury found that, notwithstanding Orthofix's refusal to renew the
distribution agreement, EBIMS's commencement of development
activities of a new external fixation system prior to the
expiration of the contract, constituted a breach of the
distribution agreement. The jury awarded compensatory damages
against the Biomet Group for breach of contract and related
claims of approximately $49 million and punitive damages of $100
million. The jury also concluded that Orthofix breached the
distribution agreement and tortiously interfered with EBIMS's
economic relations, but awarded only nominal damages to the
Biomet Group. With respect to certain non-jury issues, the trial
court entered an order denying Orthofix's motions for enhanced
and/or treble damages and attorneys' fees. The trial court also
granted Orthofix's motion for prejudgment interest, but only on
the compensatory portion of the damages commencing from November
29, 1995. On September 2, 1997, the trial court entered an
amended judgment reducing to $50 million, the $100 million in
punitive damages awarded to Orthofix by the jury. The Company
is appealing the final amended judgment entered against the
Biomet Group to the Federal Circuit.
Based on the information currently available and advice from
legal counsel, management believes that the trial court's
judgments in the Tronzo and Orthofix cases will not be upheld
upon appeal. Therefore, no amounts related to these two cases
have been recorded in the Company's financial statements, except
for estimated legal costs associated with the appeal process. If
the Company is unsuccessful in its appeal of either, or both, of
these cases, the ultimate liabilities could be material to the
operating results in the period such losses are recognized. The
Company's cash, cash equivalents and investments are adequate to
address the payment of any losses that could ultimately be
determined with respect to these two cases.
Item 4. Submission of Matters to a Vote of Security Holders.
The Annual Meeting of Shareholders of the Company was held on
September 19, 1997. At the Annual Meeting:
1. The following persons were elected as Directors of the
Company for a three-year term expiring in 2000.
Abstentions and
Name Votes For Votes Withheld Broker Non-Votes
Dane A. Miller, Ph. D. 92,497,178 57,861 None
Jerry L. Jerguson 92,459,313 90,603 None
Thomas F. Kearns, Jr. 85,146,803 129,323 None
Daniel P. Hann 92,372,027 91,028 None
The following directors will continue in office until their term expires at the
1998 Annual Meeting of Shareholders: M. Ray Harroff; Jerry L. Miller;
and Charles E. Niemier.
The following directors will continue in office until their term expires at the
1999 Annual Meeting of Shareholders: C. Scott Harrison, M.D.; Niles L. Noblitt;
Kenneth V. Miller; L. Gene Tanner; and Marilyn Tucker Quayle.
2. The selection of Coopers & Lybrand L.L.P. as certified public accountants
for the Company for the fiscal year ending May 31, 1998 was ratified by the
shareholders, as follows:
Votes For 92,268,288
Votes Against 200,910
Abstentions and Broker Non-Votes 879,791
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits. See Index to Exhibits.
(b) Reports on Form 8-K.
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
BIOMET, INC.
- - ------------
(Registrant)
DATE: 10/14/97 BY: /s/ GREGORY D. HARTMAN
-------- -------------------------
Gregory D. Hartman
Vice President - Finance
(Principal Financial Officer)
(Signing on behalf of the Registrant
and as Principal Financial Officer)
BIOMET, INC.
FORM 10-Q
INDEX TO EXHIBITS
Sequential
Number Assigned Numbering System
in Regulation S-K Page Number
Item 601 Description of Exhibit of Exhibit
- - ----------------- -------------------------------- ----------------
(2) No exhibit.
(4) 4.1 Specimen certificate for Common
Shares. (Incorporated by reference
to Exhibit 4.1 to the registrant's
Report on Form 10-K for the fiscal
year ended May 31, 1985).
4.2 Rights Agreement between Biomet,
Inc. and Lake City Bank, as Rights
Agent, dated as of December 2, 1989.
(Incorporated by reference to Exhibit
4 to Biomet, Inc. Form 8-K Current Report
dated December 22, 1989, File No. 0-12515).
(10) No exhibit.
(11) No exhibit.
(15) No exhibit.
(18) No exhibit.
(19) No exhibit.
(22) No exhibit.
(23) No exhibit.
(24) No exhibit.
(27) Financial data schedules.
(99) No exhibit.
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> MAY-31-1998
<PERIOD-END> AUG-31-1997
<CASH> 86631000
<SECURITIES> 51348000
<RECEIVABLES> 167808000
<ALLOWANCES> 5927000
<INVENTORY> 153243000
<CURRENT-ASSETS> 480873000
<PP&E> 159860000
<DEPRECIATION> 65955000
<TOTAL-ASSETS> 651487000
<CURRENT-LIABILITIES> 83231000
<BONDS> 0
<COMMON> 74132000
0
0
<OTHER-SE> 491446000
<TOTAL-LIABILITY-AND-EQUITY> 651487000
<SALES> 149529000
<TOTAL-REVENUES> 149529000
<CGS> 46622000
<TOTAL-COSTS> 58756000
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 114000
<INCOME-PRETAX> 46477000
<INCOME-TAX> 17216000
<INCOME-CONTINUING> 29261000
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 29261000
<EPS-PRIMARY> .26
<EPS-DILUTED> .26
</TABLE>
